Skip to content

Fertility and Cardiovascular Risk in Men With Metabolic Syndrome

Fertility and Cardiovascular Risk in Men With Metabolic Syndrome

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03977064
Enrollment
70
Registered
2019-06-06
Start date
2021-01-01
Completion date
2024-12-31
Last updated
2021-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metabolic Syndrome

Brief summary

Men diagnosed with metabolic syndrome (MetS) including obesity, hypertension, dyslipidemia and infertility will be assessed for cardiovascular and diabetes risk. The eligible patient will be randomised to one-year life-style intervention program including nutritional, behavioural and exercise counselling or standard care by the general physician. The aim of the program is to reduce cardiovascular and diabetes risks and hypogonadism as well.

Interventions

BEHAVIORALLife style change and weight reduction

Nutritional, behavioural, and exercise counselling to reduce body weight by 10%, normalise blood glucose, lipids, blood pressure, and testosterone level.

Sponsors

University of Giessen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Masking description

The outcomes assessor will receive pseudonymous data

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age\>18 years, wish for fatherhood in stable partnership, metabolic syndrome according to guidelines (minimum 3 out of 5 criteria), ready to participate in 1-yr lifestyle program

Exclusion criteria

* Not conforming to MetS diagnosis criteria, sterilisation, promiscuous behaviour, contraindications against established medical or surgical treatment of obesity, participation in another weight-loss program

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with normalisation of diabetes or cardiovascular risk or improvement of hypogonadism1 yearDiabetes risk Glycated hemoglobin \>5.7%, Cardiovascular risk score \>5%, Hypogonadism score increase of 20 points

Countries

Germany

Contacts

Primary ContactThomas Linn, MD
thomas.linn@innere.med.uni-giessen.de+49 641 985 57017

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026